News

Sweden boosts life sciences
Enlarge image

ResearchSweden

Sweden boosts life sciences

21.09.2012 - The Swedish Government is set to boost its life sciences industry with a US$320m investment over the next four years.

Swedish Prime Minister Fredrik Reinfeldt confirmed the country’s largest ever investment into the life sciences. Speaking at SciLifeLab in Stockholm, a major research infrastructure project aimed at maintaining the country’s position in protein science, Reinfeldt announced a package of measures totalling US$1.7bn over the next four years, of which $ 320 million is devoted to life sciences. According to the decision of Reinfeldt and four ministers, the budget of SciLifeLab will be doubled to a total of US$100m. The centre combines state-of-the-art research infrastructure with a broad knowledge in translational medicine and molecular bioscience in order to translating discoveries into both tools and therapies. Additionally, US$220m will be pumped into drug discovery, clinical research, antibiotic resistance research, health in aging and the use of patient registries. 

Most of the money will be invested into the Stockholm-Uppsala biocluster which is home to more than 50% of Sweden’s thriving life science companies. Stockholm-Uppsala Life Sciences CEO Ola Bjorkman welcomed the Prime Minister’s commitment: “In our recently published report, we pointed out the ambitious, future plans for further strengthening the life science sector in Stockholm-Uppsala, thereby ensuring that the region remains a truly global life science cluster. In particular, the investment in SciLifeLab with its cutting edge research infrastructure combined with parallel investments in drug discovery, clinical research and the use of patient registries open new avenues for developing more personalised and outcome-orientated healthcare.” 

According to a report published this August, the Stockholm-Uppsala region is one of the largest clusters in Europe. According to official sources on limited public companies, the region is home to 633 companies, which employ 23,376 staff and had a combined turnover of €20bn in 2010. More than 16,000 employees (70%) work with R&D-orientated companies while 30% are distributors. Pharmaceutical companies such as AstraZeneca (5,600 jobs) employ 13,500 staff followed by medical technology firms 4,700, biotech tools & supply enterprises such as GE Healthcare (1,225 jobs) with 2,750 (12%), CROs and other services with 1,250 staff and diagnostics companies with 1,050 jobs.

http://www.european-biotechnology-news.com/news/news/2012-03/sweden-boosts-life-sciences.html

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.54 CHF14.07%
  • SYNGENTA329.00 CHF0.27%
  • 4SC0.84 EUR0.00%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • BASILEA110.00 CHF-2.65%
  • ACTELION114.70 CHF-1.88%

TOP

  • CYTOS1.54 CHF352.9%
  • MEDIGENE13.50 EUR217.6%
  • FORMYCON26.00 EUR55.7%

FLOP

  • WILEX2.92 EUR-14.9%
  • BASILEA110.00 CHF-10.0%
  • MORPHOSYS70.55 EUR-5.6%

TOP

  • SANTHERA95.40 CHF2346.2%
  • WILEX2.92 EUR386.7%
  • FORMYCON26.00 EUR273.6%

FLOP

  • CYTOS1.54 CHF-49.7%
  • 4SC0.84 EUR-37.3%
  • THERAMETRICS0.07 CHF-36.4%

No liability assumed, Date: 26.03.2015